Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73586839" target="_blank" >RIV/61989592:15110/17:73586839 - isvavai.cz</a>

Výsledek na webu

<a href="https://data.epo.org/publication-server/pdf-document?pn=2924125&ki=B1&cc=EP" target="_blank" >https://data.epo.org/publication-server/pdf-document?pn=2924125&ki=B1&cc=EP</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance

Popis výsledku v původním jazyce

The present invention provides a method for predicting the sensitivity of a patient suffering from a cancer disease to DNA methylation inhibitor therapy, which comprises determining in vitro in cancer cells taken from the patient and comparing with values for parent type of cells - the level of expression of at least one bromodomain containing gene, and/or - the level of expression of at least one bromodomain containing protein and/or - the mutations involving the non-synonymous change in amino acid sequence of at least one bromodomain containing gene and/or - the half maximal inhibitory concentration (IC 50 ) of a DNA methylation inhibitor and/or a histone demethylase inhibitor, wherein the increase in the half maximal inhibitory concentration of the DNA methylation inhibitor and/or the histone demethylase inhibitor signifies cross-resistance, and/or - the half maximal inhibitory concentration (IC 50 ) of a selective BET bromodomain inhibitor, wherein the decrease in the half maximal inhibitory concentration of the selective BET bromodomain inhibitor signifies sensitivity. The invention further provides a combination therapy of cancers using bromodomain inhibitors in combination with DNA methylation inhibitors.

Název v anglickém jazyce

Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance

Popis výsledku anglicky

The present invention provides a method for predicting the sensitivity of a patient suffering from a cancer disease to DNA methylation inhibitor therapy, which comprises determining in vitro in cancer cells taken from the patient and comparing with values for parent type of cells - the level of expression of at least one bromodomain containing gene, and/or - the level of expression of at least one bromodomain containing protein and/or - the mutations involving the non-synonymous change in amino acid sequence of at least one bromodomain containing gene and/or - the half maximal inhibitory concentration (IC 50 ) of a DNA methylation inhibitor and/or a histone demethylase inhibitor, wherein the increase in the half maximal inhibitory concentration of the DNA methylation inhibitor and/or the histone demethylase inhibitor signifies cross-resistance, and/or - the half maximal inhibitory concentration (IC 50 ) of a selective BET bromodomain inhibitor, wherein the decrease in the half maximal inhibitory concentration of the selective BET bromodomain inhibitor signifies sensitivity. The invention further provides a combination therapy of cancers using bromodomain inhibitors in combination with DNA methylation inhibitors.

Druh

P - Patent

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/TE02000058" target="_blank" >TE02000058: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Číslo patentu nebo vzoru

EP 2924125

Vydavatel

EPO_1 -

Název vydavatele

European Patent Office

Místo vydání

Munich, The Hague, Berlin, Vienna, Brussels

Stát vydání

—

Datum přijetí

14. 6. 2017

Název vlastníka

Univerzita Palackého v Olomouci

Způsob využití

A - Výsledek využívá pouze poskytovatel

Druh možnosti využití

A - K využití výsledku jiným subjektem je vždy nutné nabytí licence